Lyrica
Product Images NDC 50436-6523

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 50436-6523). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504366523)

Lyrica 75 mg capsule label with a package size of 90 capsules. The label includes storage instructions, manufacturer information indicating Parke Davis as the manufacturer and Unit Dose Services, LLC as the packager located in Miami, FL. The label also displays the NDC 50436-6523-3, a QR code, and placeholders for lot number and expiration date.*

FDA Label Image

Cockcroft And Gault Equation (Lyrica 01)

A mathematical formula expressing creatinine clearance (CLCr) as a function of age, weight, sex, and serum creatinine level, with distinct factors for females. The formula is shown as an equation involving multiplication and division of variables in the context of pharmacokinetic calculations.*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure of pregabalin, the active ingredient in Lyrica. The diagram shows the molecular formula with its characteristic amino acid backbone and side chains, including the carboxyl and amino groups.*

FDA Label Image

Figure 1 (Lyrica 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating the effectiveness of different dosages of pregabalin compared to placebo.*

FDA Label Image

Figure 2 (Lyrica 04)

A line graph comparing percent improvement in pain from baseline to percent of patients improved, contrasting Pregabalin 100 mg three times a day versus placebo. The graph has labeled axes with vertical reference lines at intervals of percent improvement.*

FDA Label Image

Figure 3 (Lyrica 05)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline for Lyrica (pregabalin) at 75 mg, 150 mg, and 300 mg taken two times a day compared to placebo. The graph shows distinct curves for each dosage and placebo, indicating varying levels of patient improvement in pain.*

FDA Label Image

Figure 4 (Lyrica 06)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows three distinct lines illustrating efficacy differences among the treatments.*

FDA Label Image

Figure 5 (Lyrica 07)

A line graph showing the percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with threshold markers at 30% and 50% pain improvement.*

FDA Label Image

Figure 6 (Lyrica 08)

A bar chart showing responder rates (%) in two studies, Study E1 and Study E3. The horizontal axis lists different doses including placebo and various mg/day doses, while the vertical axis represents the responder rate percentage from 10% to 60%. Each dose group is represented by a vertical bar indicating response rate values, illustrating dose-dependent increases in responder rates compared to placebo.*

FDA Label Image

Figure 7 (Lyrica 09)

A line graph depicting median percent reduction in seizures from baseline versus dose in mg/day for Lyrica across four studies labeled Study E1 BID, E2 TID, E3 BID, and E3 TID. The graph shows increasing seizure reduction with higher doses up to 600 mg/day, with statistically significant p-values (p ≤ 0.0001) indicated for various dose points compared to placebo.*

FDA Label Image

Figure 8 (Lyrica 10)

A bar chart depicting responder rates (%) for three groups: Placebo (22.6%), 2.5 mg/kg/day (29.1%), and 10 mg/kg/day (40.6%). The number of subjects in each group is also shown: 93 for Placebo, 103 for 2.5 mg/kg/day, and 96 for 10 mg/kg/day.*

FDA Label Image

Figure 9 (Lyrica 11)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline for Lyrica (pregabalin) at 300 mg, 450 mg, 600 mg daily doses, and placebo. The x-axis shows pain improvement percentage from baseline, while the y-axis represents percent of patients showing improvement.*

FDA Label Image

Figure 10 (Lyrica 12)

A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR over a 180-day period. The chart compares two groups: Pregabalin, represented by a solid line, and Placebo, represented by a dashed line, with the percentage on the y-axis and days on the x-axis.*

FDA Label Image

Figure 11 (Lyrica 13)

A line graph comparing the percent of subjects improved from baseline to Week 12 using BOCF method for Pregabalin and Placebo. The x-axis shows percent improved from 0 to 100, and the y-axis shows percent of subjects improved from 0 to 100. Two lines represent improvement trends for Pregabalin and Placebo groups over this range.*

FDA Label Image

Logo (Lyrica 14)

A line graph comparing the percent of subjects improved over varying percentages of improvement from baseline to Week 16 BOCF for Pregabalin versus Placebo. The x-axis shows percent improvement, and the y-axis shows the percent of subjects improved, with Pregabalin consistently showing higher improvement than Placebo.*

FDA Label Image

Lyrica 14a

FDA Label Image

Lyrica 14b

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.